{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T18:03:16Z","timestamp":1785434596474,"version":"3.56.0"},"reference-count":21,"publisher":"The Journal of Health Economics and Outcomes Research","issue":"2","license":[{"start":{"date-parts":[[2025,7,21]],"date-time":"2025-07-21T00:00:00Z","timestamp":1753056000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["jheor.org"],"crossmark-restriction":true},"short-container-title":[],"abstract":"\n Background<\/jats:title>\n The efficacy of the combination of bortezomib, lenalidomide, and dexamethasone with daratumumab (DVRd) or isatuximab (IsaVRd) for the frontline treatment of transplant-ineligible (TIE) newly diagnosed multiple myeloma (NDMM) has been demonstrated in clinical trials. However, the treatment cost for DVRd and IsaVRd has not been compared.<\/jats:p>\n <\/jats:sec>\n \n Objectives<\/jats:title>\n To compare the drug acquisition costs (DAC) of DVRd vs IsaVRd in the first 2 years of frontline treatment for TIE patients with NDMM in the United States.<\/jats:p>\n <\/jats:sec>\n \n Methods<\/jats:title>\n Dosing schedules from the CEPHEUS and IMROZ clinical US trials were used for this analysis. AnalySource\u00ae was utilized to access the First Databank drug pricing database to collect current US DACs. Drug administration time and costs were identified and weighted, assuming 40% and 60% received the drug in a hospital outpatient and community oncology setting, respectively. Total costs were calculated by adding DACs and drug administration costs.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n The DAC was $200\u2009866 in year 1 and $137\u2009434 in year 2 for daratumumab and $212\u2009421 in year 1 and $144\u2009143 in year 2 for isatuximab. The DAC of daratumumab was $18\u2009264 (5.4%) less than isatuximab across year 1 and 2. In year 1, the total cost of DVRd per patient was $17\u2009269 and $17\u2009327 less than IsaVRd in patients <75 years and \u226575 years old, respectively. In year 2, the total cost of DVRd per patient was $10\u2009444 and $10\u2009553 less than IsaVRd in patients <75 years and \u226575 years old, respectively. Across years 1 and 2, total cost of DVRd per patient was $27\u2009713 and $27\u2009880 less than IsaVRd in patients <75 years and \u226575 years old, respectively. Compared with isatuximab, treatment with daratumumab saves 36.13 and 22.17 hours of administration time in the first and second year, respectively.<\/jats:p>\n <\/jats:sec>\n \n Discussion<\/jats:title>\n This analysis shows that the DAC of DVRd is less than IsaVRd for the frontline treatment of TIE NDMM patients. DVRd results in time savings vs IsaVRd, which is preferable for patients and caregivers.<\/jats:p>\n <\/jats:sec>\n \n Conclusions<\/jats:title>\n DVRd is a timesaving and less expensive frontline treatment option for patients with TIE NDMM than IsaVRd in the first and second year of treatment.<\/jats:p>\n <\/jats:sec>","DOI":"10.36469\/001c.141714","type":"journal-article","created":{"date-parts":[[2025,7,21]],"date-time":"2025-07-21T13:36:11Z","timestamp":1753104971000},"update-policy":"https:\/\/doi.org\/10.36469\/00001","source":"Crossref","is-referenced-by-count":2,"title":["Cost of Anti-CD38 Monoclonal Antibodies in Combination With Bortezomib, Lenalidomide and Dexamethasone for the Frontline Treatment of Transplant-Ineligible Patients With Newly Diagnosed Multiple Myeloma in the US"],"prefix":"10.36469","volume":"12","author":[{"given":"Niodita","family":"Gupta-Werner","sequence":"first","affiliation":[{"id":[{"id":"https:\/\/ror.org\/03qd7mz70","id-type":"ROR","asserted-by":"publisher"}],"name":"Johnson & Johnson (United States)","department":["Johnson & Johnson Innovative Medicine"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vipin","family":"Khare","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/03qd7mz70","id-type":"ROR","asserted-by":"publisher"}],"name":"Johnson & Johnson (United States)","department":["Johnson & Johnson Innovative Medicine"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian","family":"Macomson","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/03qd7mz70","id-type":"ROR","asserted-by":"publisher"}],"name":"Johnson & Johnson (United States)","department":["Johnson & Johnson Innovative Medicine"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rohan","family":"Medhekar","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/03qd7mz70","id-type":"ROR","asserted-by":"publisher"}],"name":"Johnson & Johnson (United States)","department":["Johnson & Johnson Innovative Medicine"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"22273","published-online":{"date-parts":[[2025,7,21]]},"reference":[{"key":"ref1","article-title":"SARCLISA\u00ae. Prescribing information","year":"2020"},{"issue":"21","key":"ref2","doi-asserted-by":"publisher","first-page":"5331","DOI":"10.3390\/cancers14215331","article-title":"Body mass index and overall survival of patients with newly diagnosed multiple myeloma","volume":"14","author":"B. Wang","year":"2022","journal-title":"Cancers (Basel)"},{"issue":"10","key":"ref3","doi-asserted-by":"publisher","first-page":"1074","DOI":"10.1634\/theoncologist.2013-0015","article-title":"Influence of body mass index on survival in veterans with multiple myeloma","volume":"18","author":"T. S. Beason","year":"2013","journal-title":"Oncologist"},{"key":"ref4","article-title":"How sarclisa is given","author":"Sarclisa","year":"2024"},{"issue":"10","key":"ref5","doi-asserted-by":"publisher","first-page":"2408","DOI":"10.3324\/haematol.2021.279459","article-title":"Final analysis of the phase III non-inferiority COLUMBA study of subcutaneous versus intravenous daratumumab in patients with relapsed or refractory multiple myeloma","volume":"107","author":"S. Z. Usmani","year":"2022","journal-title":"Haematologica"},{"key":"ref6","article-title":"Hospital Outpatient Prospective Payment System (PPS). NFRM OPPS Cost Statistics Files","author":"Centers for Medicare & Medicaid Services (CMS)","year":"2024"},{"key":"ref7","article-title":"Physician Fee Schedule Search 2024","author":"Centers for Medicare & Medicaid Services (CMS)"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"1063144","DOI":"10.3389\/fonc.2023.1063144","article-title":"Benefits of switching from intravenous to subcutaneous daratumumab: perspectives from UK healthcare providers","volume":"13","author":"G. Cook","year":"2023","journal-title":"Front Oncol"},{"issue":"3","key":"ref9","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1200\/OP-24-00501","article-title":"Stick with intravenous or give subcutaneous a shot? Time and other considerations when evaluating cancer drug formulations","volume":"21","author":"A. Gupta","year":"2025","journal-title":"JCO Oncol Pract"},{"issue":"6","key":"ref10","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1007\/s00520-004-0628-z","article-title":"Bisphosphonate infusions: patient preference, safety and clinic use","volume":"12","author":"B. Chern","year":"2004","journal-title":"Support Care Cancer"},{"issue":"9","key":"ref11","doi-asserted-by":"publisher","first-page":"e670","DOI":"10.1016\/S2352-3026(22)00165-X","article-title":"The epidemiological landscape of multiple myeloma: a global cancer registry estimate of disease burden, risk factors, and temporal trends","volume":"9","author":"J. Huang","year":"2022","journal-title":"Lancet Haematol"},{"issue":"3","key":"ref12","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1016\/j.clinthera.2019.01.009","article-title":"Cost offsets in the treatment journeys of patients with relapsed\/refractory multiple myeloma","volume":"41","author":"S. Ailawadhi","year":"2019","journal-title":"Clin Ther"},{"issue":"8","key":"ref13","doi-asserted-by":"publisher","first-page":"922","DOI":"10.18553\/jmcp.2019.25.8.922","article-title":"Modeling the budgetary impact of payer utilization management strategies: an adapted framework based on lessons learned","volume":"25","author":"A. Hung","year":"2019","journal-title":"J Manag Care Spec Pharm"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"662","DOI":"10.1200\/EDBK_200867","article-title":"Value and cost of myeloma therapy","volume":"38","author":"S.V. Rajkumar","year":"2018","journal-title":"Am Soc Clin Oncol Educ Book"},{"issue":"suppl 1","key":"ref15","doi-asserted-by":"publisher","first-page":"S3","DOI":"10.1002\/ajh.26512","article-title":"Current approaches to management of newly diagnosed multiple myeloma","volume":"97","author":"U. Goel","year":"2022","journal-title":"Am J Hematol"},{"issue":"7","key":"ref16","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1002\/ajh.25797","article-title":"Transplant eligibility in elderly multiple myeloma patients: prospective external validation of the international myeloma working group frailty score and comparison with clinical judgment and other comorbidity scores in unselected patients aged 65-75 years","volume":"95","author":"A. Belotti","year":"2020","journal-title":"Am J Hematol"},{"issue":"17","key":"ref17","doi-asserted-by":"publisher","first-page":"1597","DOI":"10.1056\/NEJMoa2400712","article-title":"Isatuximab, bortezomib, lenalidomide, and dexamethasone for multiple myeloma","volume":"391","author":"T. Facon","year":"2024","journal-title":"N Engl J Med"},{"issue":"4","key":"ref18","doi-asserted-by":"publisher","first-page":"1195","DOI":"10.1038\/s41591-024-03485-7","article-title":"Daratumumab plus bortezomib, lenalidomide and dexamethasone for transplant-ineligible or transplant-deferred newly diagnosed multiple myeloma: the randomized phase 3 CEPHEUS trial","volume":"31","author":"S. Z. Usmani","year":"2025","journal-title":"Nat Med"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"TPS8056","DOI":"10.1200\/JCO.2019.37.15_suppl.TPS8056","article-title":"Bortezomib, lenalidomide, and dexamethasone (VRd) \u00b1 daratumumab (DARA) in patients (pts) with newly diagnosed multiple myeloma (NDMM) for whom transplant is not planned as initial therapy: a multicenter, randomized, phase III study (CEPHEUS)","volume":"37","author":"S. Zweegman","year":"2019","journal-title":"J Clin Oncol"},{"key":"ref20","article-title":"AnalySource\u00ae: premier access to the First Databank drug pricing database 2025","author":"AnalySource\u00ae"},{"key":"ref21","article-title":"Darzalex Faspro Package Insert","author":"Janssen","year":"2024"}],"updated-by":[{"DOI":"10.36469\/001c.143106","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2025,8,12]],"date-time":"2025-08-12T00:00:00Z","timestamp":1754956800000}}],"container-title":["Journal of Health Economics and Outcomes Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jheor.org\/article\/141714-cost-of-anti-cd38-monoclonal-antibodies-in-combination-with-bortezomib-lenalidomide-and-dexamethasone-for-the-frontline-treatment-of-transplant-ineli","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T19:07:13Z","timestamp":1779390433000},"score":1,"resource":{"primary":{"URL":"https:\/\/jheor.org\/article\/141714-cost-of-anti-cd38-monoclonal-antibodies-in-combination-with-bortezomib-lenalidomide-and-dexamethasone-for-the-frontline-treatment-of-transplant-ineli"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,21]]},"references-count":21,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.36469\/001c.141714","relation":{},"ISSN":["2327-2236"],"issn-type":[{"value":"2327-2236","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,21]]}}}